Pfizer Corporation

Nerviano Medical Sciences S.r.l.

Pharmacia Italia S.p.a.

Paola Civaroli

Alessandro Martini

Lorena Muggetti

Ermes Vanotti

Massimo Zampieri

Maria Gioia Fornaretto

Christopher James

The present invention relates to novel crystalline salts of a CDC7 or CDC7/CDKs inhibitor, to a novel crystal form of the corresponding free base, to a process for their preparation, to hydrates, solvates and polymorphs of such new salt forms, to their use in therapy and to pharmaceutical compositions containing them. Such crystal salts are selected from L-asparate, hemifumarate, hydrochloride, maleate, mesylate, sulfate, L-tartrate or phosphate salts of 5-(2-amino-pyrimidin-4-yl)-2-(2,4-dichloro-phenyl)-1H-pyrrole-3-carboxylic acid amide.

Crystalline CDC7 inhibitor salts

The present invention relates to a semi-solid filling medium which comprises a camptothecin derivative; a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride; and an effective thickening-reducing and stabilizing-promoting amount of one or more pharmaceutically acceptable excipients.

Oral formulations for anti-tumor compounds

An oral pharmaceutical formulation, which comprises, in a hydroxypropylmethylcellulose capsule, a camptothecin analogue dispersed or solubilized in a semi-solid matrix of a polyethyleneglycol with a molecular weight ranging from 400 to 20000.

Pharmaceutical formulations in hydroxypropylmethylcellulose capsules

Growing community of inventors

Milan, Italy

Paola Civaroli